-

LivaNova Elects Peter Wilver to Board of Directors

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Peter Wilver has been elected to the Board of Directors, effective immediately. His election was part of the LivaNova 2022 Annual General Meeting of Shareholders (AGM) held on June 13.

Wilver joins the LivaNova Board with more than 30 years of business experience. He retired from Thermo Fisher Scientific, Inc., a provider of laboratory products and services, in 2017 after serving as the company’s Executive Vice President and Chief Administrative Officer since 2015, as well as Senior Vice President and Chief Financial Officer from 2006-2015. He served as Thermo Electron’s Vice President and Chief Financial Officer from 2004-2006, having previously been Vice President, Financial Operations from 2000-2004. Throughout his career, he held financial leadership roles at Honeywell International, Grimes Aerospace Company and General Electric Company. Other public company directorships in the past five years include Evoqua Water Technologies Corporation (current), Shoals Technology Group (current), CIRCOR International, Inc. and Tenet Healthcare Corporation.

“Pete offers a wealth of strategic planning, business development and financial experience with large, multinational manufacturing companies that will bring additional acumen to our accomplished Board of Directors,” said William Kozy, LivaNova Board Chair. “The Board welcomes Pete and looks forward to his engagement and contributions.”

Wilver joins eight other professionals who were re-elected to their Board seats.

About LivaNova

LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 3,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding changes to the Company’s Board of Directors. Actual events may differ materially from those indicated in forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contacts

LivaNova Investor Relations and Media Contacts
+1 281-895-2382
Lindsey Little
Senior Director, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com

LivaNova PLC

NASDAQ:LIVN
Details
Headquarters: London, United Kingdom
CEO: Vladimir Makatsaria
Employees: 3000
Organization: PUB
Revenues: $1.25B (2024)
Net Income: $63.2M (2024)

Release Summary
LivaNova PLC today announced Peter Wilver has been elected to the Board of Directors, effective immediately.
Release Versions

Contacts

LivaNova Investor Relations and Media Contacts
+1 281-895-2382
Lindsey Little
Senior Director, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com

More News From LivaNova PLC

Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy

GLOUCESTER, England--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS study, the first long-term effectiveness evaluation of contemporary VNS Therapy™ devices in people with Drug-Resistant Epilepsy (DRE). The article, “CORE-VNS Seizure and Non-Seizure 36 Month Outcomes in People with Drug-resistant Epilepsy,”1 re...

LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November

GLOUCESTER, England--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that members of the Company’s Executive Leadership Team will provide general business updates during fireside chats at the four following November healthcare conferences: UBS Global Healthcare Conference on Mon., Nov. 9, from 11-11:35 a.m. EST in Palm Beach, Fla. 8th Annual Wolfe Research Healthcare Conference on Tues., Nov. 10, from 9:20-9:50 a.m. EST in New York City...

LivaNova to Announce Third-Quarter 2026 Results

GLOUCESTER, England--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2026 results prior to the call.The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the...
Back to Newsroom